Bictegravir（Cat No.:I004238）is an antiretroviral medication used in the treatment of HIV-1 infection. It is a potent integrase strand transfer inhibitor (INSTI) that works by blocking the action of the HIV integrase enzyme, preventing the viral DNA from integrating into the host cell genome. This action is crucial for halting the replication of the virus. Bictegravir is commonly used as part of a combination therapy, offering a once-daily regimen with high efficacy and a favorable safety profile. It plays a vital role in modern HIV treatment, helping to achieve and maintain viral suppression.
| Catalog Number | I004238 |
| CAS Number | 1611493-60-7 |
| Synonyms | GS-9883; GS 9883; GS9883; GS-9883-01; Bictegravir;(2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1/’,2/’:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| Molecular Formula | C21H18F3N3O5 |
| Purity | 98% |
| Target | HIV IN |
| Target Protein | P03366 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | IC50: 7.5 nM(HIV-1 integrase) |
| IUPAC Name | (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide |
| InChI | InChI=1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1 |
| InChIKey | SOLUWJRYJLAZCX-LYOVBCGYSA-N |
| SMILES | C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F |
